



Adrienne H. Long, MD, PhD

Instructor, Pediatrics - Hematology & Oncology

CLINICAL OFFICE (PRIMARY)

- **Pediatric Hematology and Oncology**

750 Welch Rd Ste 200

MC 5798

Palo Alto, CA 94304

Tel (650) 723-5535 **Fax** (650) 498-6937

Bio

BIO

Adrienne H. Long, MD, PhD is an instructor in the Division of Pediatric Hematology and Oncology at the Lucile Packard Children's Hospital at Stanford. Dr. Long attend Northwestern University, where she earned both her BS in biomedical engineering and her MD. Determined to help develop novel treatments for pediatric cancer patients, she took time during medical school to pursue a PhD at the National Institutes of Health (NIH), where she helped advance CAR T cell therapies with Dr. Crystal Mackall. Her influential thesis work was the first to identify T cell exhaustion as a critical factor limiting efficacy of CAR therapies (Long et al., Nature Medicine, 2015), and also identified novel methods to enhance CAR therapies for pediatric solid tumor patients (Long/Highfill et al., Cancer Immunology Research, 2016). Dr. Long went on to complete her pediatrics residency training at Boston Children's Hospital, where she continued her research in cancer immunology with Dr. Nicholas Haining – this time focusing on strategies to enhance antigen presentation to augment checkpoint blockade (Long et al. Keystone Symposium on Cancer Immunotherapy, 2019). She completed her pediatric oncology fellowship at Stanford, and remains dedicated to a career as a physician-scientist focused on developing novel immunotherapies for children with cancer. She is currently conducting her post-doctoral research with Dr. Mark Davis, studying how thymic selection, designed to prevent auto-immunity, may also inhibit antitumor immunity in children.

CLINICAL FOCUS

- Cancer Immunology and Immunotherapy
- Pediatric Hematology-Oncology

ACADEMIC APPOINTMENTS

- Instructor, Pediatrics - Hematology & Oncology
- Member, Maternal & Child Health Research Institute (MCHRI)

HONORS AND AWARDS

- Young Investigator Award, Hyundai Hope on Wheels (2023)
- Young Investigator Award in Translational Cancer Research, American Association for Cancer Research - American Society of Clinical Oncology (2022)
- Physician Scientist Fellow, Doris Duke Charitable Foundation (2021)

- Anne T. and Robert M. Bass Endowed Fellow, Stanford Maternal and Child Health Research Institute (2020)
- Fredrick H. Lovejoy, Jr. Award, Boston Children's Hospital (2019)
- Member, Alpha Omega Alpha Honor Medical Society (2015)
- Scholar-in-Training Award, American Association for Cancer Research (2015)
- Women in Cancer Research Award, American Association for Cancer Research (2014)
- Fellows Award for Research Excellence, National Institutes of Health (2013)
- Cloister Research Scholar, Howard Hughes Medical Institute - National Institutes of Health (2011)

PROFESSIONAL EDUCATION

- Board Certification: Pediatric Hematology-Oncology, American Board of Pediatrics (2023)
- Fellowship: Stanford University Pediatric Hematology Oncology Fellowship (2022) CA
- Board Certification: Pediatrics, American Board of Pediatrics (2020)
- Residency: Boston Children's Hospital Pediatric Residency (2019) MA
- Medical Education: Northwestern University Feinberg School of Medicine (2016) IL
- PhD, National Institutes of Health, Cancer Immunology (2015)
- BS, Northwestern University, Biomedical Engineering (2008)

Publications

PUBLICATIONS

- **4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors** *NATURE MEDICINE*
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., Kaplan, R. N., Patterson, G. H., Fry, et al
2015; 21 (6): 581-590
- **Development of clinical pathways to improve multidisciplinary care of high-risk pediatric oncology patients.** *Frontiers in oncology*
Reschke, A., Richards, R. M., Smith, S. M., Long, A. H., Marks, L. J., Schultz, L., Kamens, J. L., Aftandilian, C., Davis, K. L., Gruber, T., Sakamoto, K. M.
2022; 12: 1033993
- **Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
Long, A. H., Morgenstern, D. A., Leruste, A., Bourdeaut, F., Davis, K. L.
2022; 42: 1-14
- **Delayed cancer diagnoses and high mortality in children during the COVID-19 pandemic.** *Pediatric blood & cancer*
Ding, Y., Ramakrishna, S., Long, A. H., Phillips, C. A., Montiel-Esparza, R., Diorio, C. J., Bailey, L. C., Maude, S. L., Aplenc, R., Batra, V., Reilly, A. F., Rheingold, S. R., Lacayo, et al
2020: e28427
- **Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade.** *Nature*
Ishizuka, J. J., Manguso, R. T., Cheruiyot, C. K., Bi, K. n., Panda, A. n., Iracheta-Vellve, A. n., Miller, B. C., Du, P. P., Yates, K. B., Dubrot, J. n., Buchumenski, I. n., Comstock, D. E., Brown, et al
2019; 565 (7737): 43-48
- **Hypotonia and Lethargy in a Two-Day-Old Male Infant.** *Pediatrics*
Long, A. H., Fiore, J. G., Gillani, R. n., Douglass, L. M., Fujii, A. M., Hoffman, J. D.
2019; 144 (1)
- **Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.** *Molecular therapy : the journal of the American Society of Gene Therapy*
Walker, A. J., Majzner, R. G., Zhang, L. n., Wanhainen, K. n., Long, A. H., Nguyen, S. M., Lopomo, P. n., Vigny, M. n., Fry, T. J., Orentas, R. J., Mackall, C. L.
2017

- **Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas** *CANCER IMMUNOLOGY RESEARCH*
Long, A. H., Highfill, S. L., Cui, Y., Smith, J. P., Walker, A. J., Ramakrishna, S., El-Etriby, R., Galli, S., Tsokos, M. G., Orentas, R. J., Mackall, C. L.
2016; 4 (10): 869-880
- **Chimeric Antigen Receptors for Cancer: Progress and Challenges** *CURRENT STEM CELL REPORTS*
Long, A. H., Lee, D. W., Mackall, C. L.
2015; 1 (4): 187-196
- **Comparison against 186 canid whole-genome sequences reveals survival strategies of an ancient clonally transmissible canine tumor** *GENOME RESEARCH*
Decker, B., Davis, B. W., Rimbault, M., Long, A. H., Karlins, E., Jagannathan, V., Reiman, R., Parker, H. G., Droegemueller, C., Corneveaux, J. J., Chapman, E. S., Trent, J. M., Leeb, et al
2015; 25 (11): 1646-55
- **4-1BB costimulation ameliorates exhaustion and prolongs in vivo persistence of chimeric antigen receptor (CAR) expressing T cells**
Long, A. H., Haso, W. M., Smith, J. P., Walker, A. J., Fry, T. J., Orentas, R. J., Mackall, C. L.
AMER ASSOC CANCER RESEARCH.2015
- **14g2a-based GD2-specific chimeric antigen receptors (CARs) constitutively signal, leading to rapidly induced T-cell exhaustion and poor antitumor efficacy in vivo**
Long, A., Orentas, R. J., Mackall, C. L.
AMER ASSOC CANCER RESEARCH.2014
- **Synthetic Chimeric Antigen Receptors (CARs) Rapidly Induce Exhaustion and Augmented Glycolytic Metabolism In Human T Cells and Implicate Persistent CD28 Signaling As a Driver Of Exhaustion In Human T Cells**
Long, A. H., Orentas, R. J., Mackall, C. L.
AMER SOC HEMATOLOGY.2013
- **Evaluating the susceptibility of solid tumors to chimeric antigen receptor modified T cell therapies**
Long, A. H., Highfill, S. L., Haso, W. M., Orentas, R. J., Mackall, C. L.
AMER ASSOC CANCER RESEARCH.2013
- **Lessons learned from a highly-active CD22-specific chimeric antigen receptor.** *Oncoimmunology*
Long, A. H., Haso, W. M., Orentas, R. J.
2013; 2 (4): e23621
- **Evaluating the Susceptibility of Solid Tumors to Chimeric Antigen Receptor Modified T Cell Therapies**
Long, A. H., Haso, W., Lee, D., Highfill, S., Orentas, R., Mackall, C.
LIPPINCOTT WILLIAMS & WILKINS.2012: 726
- **Triggered release of therapeutic antibodies from nanodiamond complexes** *NANOSCALE*
Smith, A. H., Robinson, E. M., Zhang, X., Chow, E. K., Lin, Y., Osawa, E., Xi, J., Ho, D.
2011; 3 (7): 2844-48
- **Improved methods and standards for telomerase detection: quantitative histopathology using antibody staining** *BIOTECHNIC & HISTOCHEMISTRY*
Jakupciak, J. P., Gallant, N. D., Smith, A. H., Becker, M. L., Tona, A., Atha, D. H.
2009; 84 (5): 195-206
- **Properties of ceramics in the system ZrB₂-Ta₅Si₃** *JOURNAL OF MATERIALS RESEARCH*
Talmy, I. G., Zaykoski, J. A., Opeka, M. M., Smith, A. H.
2006; 21 (10): 2593-99

PRESENTATIONS

- Inhibition of signal peptide peptidase triggers novel antigen presentation on non-classical MHC and sensitizes tumors to checkpoint blockade - Keystone Symposia - Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit (2019)
- 4-1BB costimulation ameliorates exhaustion and prolongs in vivo persistence of chimeric antigen receptor (CAR) expressing T cells - American Association for Cancer Research Annual Meeting (2015)
- 14g2a based GD2 specific chimeric antigen receptors constitutively signal, leading to rapidly induced T cell exhaustion and poor anti-tumor efficacy in vivo - American Association for Cancer Research Annual Meeting (2014)

- Synthetic chimeric antigen receptors (CARs) rapidly induce exhaustion and augmented glycolytic metabolism in human T cells - American Society of Hematology Annual Meeting (2013)